SBIR-STTR Award

Magnetic Resonance Imaging Subsystem For Evaluation Of Valvular Disease
Award last edited on: 2/5/13

Sponsored Program
SBIR
Awarding Agency
NIH : NHLBI
Total Award Amount
$1,199,557
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Juan M Santos

Company Information

HeartVista Inc

998 Hamilton Avenue
Menlo Park, CA 94025
   (650) 948-2428
   N/A
   www.heartvista.com
Location: Single
Congr. District: 18
County: San Mateo

Phase I

Contract Number: 1R43HL092691-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2008
Phase I Amount
$140,712
Cardiac magnetic resonance imaging has been shown to be one of the best technologies for the evaluation of cardiovascular pathologies. The broad application of this promising technology is expected to significantly improve the treatment of patients with heart disease. Valvular heart diseases are a common set of problems that need to be considered in any patient with heart complaints because of extensive symptomatic overlaps with other diseases. While MRI has been demonstrated to be very helpful in quantitating all aspects of this condition beyond conventional echocardiography, no commercial software package has been able to translate that advantage into routine clinical care. The aim of this application is to develop a commercial robust cardiovascular subsystem that will enable the broad application of this technology to the clinical realm. Specifically, during Phase I of this proposal, HeartVista will develop and test a quantitative cardiovascular valvular evaluation software that integrates into an environment for rapid cardiovascular imaging. This package will include real-time evaluation of cardiac output, real-time ventricular function evaluation, real-time color flow quantitation, and real-time "doppler" measurements. We further expect to collect 40 patient examinations for feedback and analysis in anticipation of full productization. Under previous NIH grant support through Stanford University, we have established real-time rapid imaging sequences for the assessment of cardiac output and color-flow mapping. We have also established the utility and accuracy of rapid whole-heart ventricular function assessment. Our goal in this proposal is to integrate these methods into a robust valvular heart disease system to realize the clinical potential of cardiac MRI in the quantitative evaluation of common cardiac complaints. Generally, our methods concern 7 obtaining adequate temporal resolution, spatial coverage, and contrast production for color-flow imaging using customized pulse sequences and hardware to reduce data acquisition time, 7 developing a underlying real-time imaging platform that allows the seamless real-time integration of receiver coil functions, pulse sequences, and post-processing and display that optimizes the workflow for studying patients with valvular disease. This proposal focuses on developing and validating this combined examination to provide the clinician a robust and intuitive complete quantitative cardiac evaluation package that can be performed comfortably in about 1/2 hour.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.

Phase II

Contract Number: 2R44HL092691-02
Start Date: 9/30/08    Completed: 7/31/13
Phase II year
2011
(last award dollars: 2012)
Phase II Amount
$1,058,845

Valvular heart diseases are conventionally overshadowed by the very high prevalence of coronary disease. However, moderate to severe valvular heart disease is present in more than 12% of patients over the age of 70 and present in 80% or more of patients admitted with congestive heart failure [1]. The proper cardiac evaluation must therefore include an accurate evaluation of valvular structure and function. Cardiac magnetic resonance imaging has been shown to be one of the best technologies for the evaluation of valvular pathologies. The broad application of this promising technology is expected to significantly improve the treatment of patients with heart diseases. However, widespread adoption of this beneficial technology has been held back by the lack of both software infrastructure and specific software sequences that take advantage of this infrastructure to provide a complete cardiac examination that can be performed rapidly in the clinical environment. The aim of this application is to develop a commercial robust cardiovascular subsystem that will enable the broad application of this technology to the clinical realm. Under previous NIH grant support through Stanford University, we have established real-time rapid imaging se- quences for the assessment of wall motion, valvular morphology, color flow mapping and quantitation of valvular steno- sis. We have also established the feasibility of rapidly quantitating each of these parameters. Our goal in this proposal is to integrate these methods into a robust valvular heart disease system to realize the clinical potential of cardiac MRI in the complete evaluation of heart disease. During Phase I of this proposal, HeartVista developed and tested the alpha version of the cardiovascular software infrastructure that provides an integrated environment for rapid valvular imaging. This package includes real-time evaluation of ventricular function, real-time quantitative flow mapping, interrogation of high-velocity jets, and detailed assessment of valvular morphology. We installed the system at selected alpha sites and collected patient data. Generally, our methods concern 7 obtaining adequate temporal resolution, spatial coverage, and contrast production for valvular imaging using customized pulse sequences and hardware to reduce data acquisition time, 7 developing a underlying real-time imaging platform that allows the seamless real-time integration of receiver coil functions, pulse sequences, and post-processing and display that optimizes the workflow for studying patients with valvular disease. This proposal focuses on developing and validating this combined examination to provide the clinician a robust and intuitive complete cardiac evaluation package that can be performed comfortably in less than 1 hour. During Phase II of this proposal, we will continue the development of our product based on the feedback obtained during Phase I and we will conduct a clinical study to demonstrate the non-inferiority of our product compared with conventional cardiovascular MRI examinations in robustness and diagnostic accuracy.

Public Health Relevance:
Valvular heart disease is increasingly common in our aging population in the United States. Valvular disease com- plicates as many as 80% of patients admitted for heart failure [2], and moderate to severe valvular heart disease is present in more than 12% of patients over the age of 70 [1]. The evaluation of common cardiac complaints such as shortness of breath must always include an assessment of valvular heart disease. Conventional echocardiography provides excellent qualitative data but does not provide quantitative information on all the important parameters relating to valvular disease. Current MRI techniques are quantitative but have significant shortcomings related to usability and prolonged examination times. A comprehensive valvular examination is therefore not normally part of a cardiac MRI examination. However, ad hoc or ""incidental"" examination is important given the prevalence of valvular disease that is co-morbid in other heart conditions. Given the enormous number of these patients, even a modest improvement in diagnostic accuracy will have a large public-health impact. Cardiac magnetic resonance imaging has been shown to be one of the best technologies for the evaluation of cardiovascular pathologies. It is the only imaging modality that could qualitatively and quantitatively measure all of the important valvular parameters including ventricular function, cardiac output, valvular regurgitation and valvular stenosis in a single examination. The broad application of this promising technology is expected to significantly improve the treatment of patients with heart disease. However, the adoption of this beneficial technology has been held back by the lack of both a software infrastructure and specific software sequences that take advantage of this infrastructure to provide a complete cardiovascular examination that can be performed rapidly in the clinical environment. The aim of this application is to develop a robust commercial cardiovascular subsystem that will enable the broad clinical application of this technology.

Thesaurus Terms:
Accuracy Of Diagnosis;Acute;Admission;Admission Activity;Adoption;Affect;Age;Back;Cardiac;Cardiac Diseases;Cardiac Disorders;Cardiac Failure Congestive;Cardiac Output;Cardiovascular;Cardiovascular Body System;Cardiovascular Diseases;Cardiovascular Organ System;Cardiovascular Pathology;Cardiovascular System;Cardiovascular System (All Sites);Clinic;Clinical;Clinical Evaluation;Clinical Research;Clinical Study;Clinical Testing;Color;Communities;Computer Software;Congestive Heart Failure;Coronary Disease;Coronary Heart Disease;Data;Development;Diagnostic;Disease;Disorder;Dorsum;Dysfunction;Echocardiogram;Echocardiography;Echography;Echotomography;Environment;European;Evaluation;Feedback;Functional Disorder;Funding;Goals;Grant;Heart;Heart Decompensation;Heart Diseases;Heart Valve Diseases;Heart Vascular;Heart Failure;High Prevalence;Hospitals;Hour;Image;Imaging Technology;Individual;Infrastructure;Ischemia;Ischemic Heart;Ischemic Heart Disease;Ischemic Myocardium;Loinc Axis 4 System;Laboratory Research;Mr Imaging;Mr Tomography;Mri;Magnetic Resonance Imaging;Magnetic Resonance Imaging Scan;Maps;Marketing;Measurement;Measures;Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance;Medical Ultrasound;Methods;Modality;Morphology;Motion;Myocardial;Myocardial Ischemia;Nhlbi;Nih;Nmr Imaging;Nmr Tomography;National Heart, Lung, And Blood Institute;National Institutes Of Health;Nuclear Magnetic Resonance Imaging;Pathologic Constriction;Pathological Constriction;Pathology;Patients;Pericardial;Pericardial Body Location;Phase;Physicians;Physiologic Pulse;Physiopathology;Prevalence;Process;Production;Public Health;Pulse;Research Infrastructure;Resolution;Rough-Toothed Dolphin;Sbir;Sbirs (R43/44);Sales;Shortness Of Breath;Site;Small Business Innovation Research;Small Business Innovation Research Grant;Software;Steno;Stenosis;Structure;Symptoms;System;Techniques;Technology;Testing;Time;Transthoracic Echocardiography;Ultrasonic Imaging;Ultrasonogram;Ultrasonography;Ultrasound Diagnosis;Ultrasound Medical Imaging;Ultrasound Test;United States;United States National Institutes Of Health;Universities;Valvular Heart Diseases;Valvular Heart Disorder;Ventricular Function;Zeugmatography;Aging Population;Base;Cardiac Failure;Cardiac Valve Disease;Cardiac Valve Disorder;Cardiac Valvular Disease;Cardiovascular Disorder;Circulatory System;Clinical Applicability;Clinical Application;Clinical Care;Clinical Test;Computer Program/Software;Coronary Disorder;Data Acquisition;Developmental;Diagnostic Accuracy;Diagnostic Ultrasound;Disease/Disorder;Heart Disorder;Heart Ischemia;Heart Output;Heart Sonography;Heart Valve Disorder;Imaging;Imaging Method;Imaging Modality;Improved;Myocardial Ischemia/Hypoxia;Myocardium Ischemia;Pathophysiology;Population Aging;Prospective;Public Health Medicine (Field);Research Clinical Testing;Sonogram;Sonography;Sound Measurement;Tool;Ultrasound;Ultrasound Imaging;Ultrasound Scanning;Usability